Non‐Prescribed Gabapentinoid Use: Demographic and Behavioural Risk Profiles in a Large International Sample
Drug and Alcohol Review · 2026
DOI: 10.1111/dar.70248 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug and Alcohol Review, 2026. Verfasst von Jennifer Seddon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Psychological Research, Oxford Brookes University, Oxford, UK. Hauptthemen laut MEDLINE: Gabapentin, Substance-Related Disorders, Nonprescription Drugs. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Government Department of Health, Disability and Ageing, National Health and Medical Research Council, Department of Health, Disability and Ageing.
Abstract (Originalsprache)
Introduction
The harm potential of gabapentinoids is well established, with concerns about non‐medical use increasing alongside prescribing rates. However, less is known about the characteristics of people who use gabapentinoids obtained through non‐prescribed routes. This study explored demographic and behavioural factors associated with gabapentinoid use, including differences between prescribed and non‐prescribed sources.
Method
Data from the Global Drug Survey 2021 ( N = 24,954). Multivariable logistic regression models identified correlates of: (i) past‐year use; (ii) prescribed versus non‐prescribed acquisition; and (iii) using gabapentinoids prescribed to others versus prescribed to oneself.
Results
Past‐year gabapentinoid use was reported by 2.9% of respondents. In adjusted models, past‐year use was associated with being a man, reporting a mental health or neurodevelopmental condition, use of benzodiazepines, opioids and illicit drugs. Among respondents who had ever used gabapentinoids ( N = 1112), 45.6% reported using their own prescription, 27.2% used a non‐prescribed source and 27.2% used medication prescribed to someone else. Non‐prescribed use (i.e., not from a personal prescription) was more common among younger respondents, cis men and those reporting illicit drug or benzodiazepine use. Respondents with mental health or neurodevelopmental conditions were more likely to report prescribed use. Discussion and Conclusions A substantial proportion of gabapentinoid use occurs outside formal prescribing pathways, including use of medications prescribed to others. Non‐prescribed use is embedded within broader substance use behaviours, highlighting specific demographic groups with higher odds of nonprescribed use. These findings underscore the importance of targeted harm‐reduction responses and continued attention to diversion‐prevention strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Psychological Research, Oxford Brookes University, Oxford, UK.
- National Drug Research Institute and enAble Institute, Curtin University, Perth, Australia.
- Harm and Risk Reduction Program, Burnet Institute, Melbourne, Australia.
- National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.
- School of Public Health, The University of Queensland, Brisbane, Australia.
- Centre for Health Services Research, The University of Queensland, Brisbane, Australia.
ORCID-Profile: Jennifer Seddon, Monica J Barratt, Cheneal Puljević, Jason A Ferris, Adam R Winstock, Emma L Davies
Förderung
- Australian Government Department of Health, Disability and Ageing
- National Health and Medical Research Council
- Department of Health, Disability and Ageing
Zitieren
APA
Seddon, J., Barratt, M. J., Puljević, C., Ferris, J. A., Winstock, A. R., & Davies, E. L. (2026). Non‐Prescribed Gabapentinoid Use: Demographic and Behavioural Risk Profiles in a Large International Sample. Drug and Alcohol Review. https://doi.org/10.1111/dar.70248
Vancouver
Seddon J, Barratt MJ, Puljević C, Ferris JA, Winstock AR, Davies EL. Non‐Prescribed Gabapentinoid Use: Demographic and Behavioural Risk Profiles in a Large International Sample. Drug and Alcohol Review. 2026. doi:10.1111/dar.70248
BibTeX
@article{Seddon2026,
author = {Seddon, Jennifer and Barratt, Monica J and Puljević, Cheneal and Ferris, Jason A and Winstock, Adam R and Davies, Emma L},
title = {Non‐Prescribed Gabapentinoid Use: Demographic and Behavioural Risk Profiles in a Large International Sample},
journal = {Drug and Alcohol Review},
year = {2026},
doi = {10.1111/dar.70248}
}
EUVIMED